SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation
Article 2024 en
Authors
YC
Yi‐Hsin Chan
TC
Tze‐Fan Chao
SC
Shao-Wei Chen
Abstract
1 min read
Considering the high risk of developing HF and/or high prevalence of concomitant HF in patients with concomitant diabetes and AF, whether SGLT2is should be the preferred treatment to GLP-1RAs for such a high-risk population requires further investigation.
Professor Gregory Lip, Cécile Laroche, Mircea Ioachim Popescu, Lars Hvilsted Rasmussen, Laura Vitali Serdoz, Gheorghe‐Andrei Dan, Zbigniew Kalarus, Harry J.G.M. Crijns, Mário Oliveira, Luigi Tavazzi, Aldo Maggioni, Giuseppe Boriani
Discussion(0)
No comments yet. Be the first to comment.